A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
Public ClinicalTrials.gov record NCT03495921. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma
Study identification
- NCT ID
- NCT03495921
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Gradalis, Inc.
- Industry
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Interventions
- Vigil Biological
- Irinotecan Drug
- Temozolomide Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 2 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 20, 2018
- Primary completion
- Jan 19, 2022
- Completion
- Jan 19, 2022
- Last update posted
- Apr 25, 2023
2018 – 2022
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arkansas Children's Hospital | Little Rock | Arkansas | 72202 | — |
| Southern California Permanente Medical Group | Los Angeles | California | 90027 | — |
| Mayo Clinic Florida | Jacksonville | Florida | 32224 | — |
| Nicklaus Children's Hospital | Miami | Florida | 33155 | — |
| Dana-Farber/Boston Children's Cancer and Blood Disorders | Boston | Massachusetts | 02215 | — |
| Washington University Siteman Cancer Center | St Louis | Missouri | 63110 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Duke Children's Hospital and Health Center; Duke Cancer Institute | Durham | North Carolina | 27710 | — |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | 45229 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Texas Oncology - Pediatrics | Dallas | Texas | 75230 | — |
| Cook Children's Medical Center | Fort Worth | Texas | 76104 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03495921, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 25, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03495921 live on ClinicalTrials.gov.